

Cleansing Notice under Section 708A of the Corporations Act 2001 (Cth)

Melbourne, Australia – 11 November 2025: Adherium Limited (ASX: ADR) (the Company), as a result of the exercise of 494,501,041 options, has issued and allotted fully paid ordinary shares (Shares) at an issue price of \$0.005 each to raise \$2,472,505.205. Refer to the Appendix 2A dated 11 November 2025 for further details of the Share issue.

For the purposes of sections 708A(5)(e)(i) and 708A(6) of the Corporations Act 2001 (Cth) (Corporations Act), the Company advises:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) that is required to be disclosed.

For more information about Adherium and its revolutionary respiratory solutions, please visit adherium.com.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

investors@adherium.com

Media Enquiries:

Haley Chartres

H[^]CK

Director

haley@hck.digital



ASX Release

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at [adherium.com](https://www.adherium.com)